- Home
- CMMB vs DXST Comparison
CMMB vs DXST Comparison
Compare CMMB & DXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- DXST
- Stock Information
- Founded
- CMMB 2004
- DXST 2011
- Country
- CMMB Israel
- DXST China
- Employees
- CMMB N/A
- DXST N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- DXST
- Sector
- CMMB Health Care
- DXST
- Exchange
- CMMB Nasdaq
- DXST NYSE
- Market Cap
- CMMB 22.0M
- DXST 18.7M
- IPO Year
- CMMB N/A
- DXST 2025
- Fundamental
- Price
- CMMB $1.13
- DXST $1.15
- Analyst Decision
- CMMB Strong Buy
- DXST
- Analyst Count
- CMMB 2
- DXST 0
- Target Price
- CMMB $8.50
- DXST N/A
- AVG Volume (30 Days)
- CMMB 187.2K
- DXST 27.6K
- Earning Date
- CMMB 08-20-2025
- DXST 01-01-0001
- Dividend Yield
- CMMB N/A
- DXST N/A
- EPS Growth
- CMMB N/A
- DXST 13.11
- EPS
- CMMB N/A
- DXST 0.14
- Revenue
- CMMB N/A
- DXST $11,542,292.00
- Revenue This Year
- CMMB N/A
- DXST N/A
- Revenue Next Year
- CMMB N/A
- DXST N/A
- P/E Ratio
- CMMB N/A
- DXST $8.42
- Revenue Growth
- CMMB N/A
- DXST 22.18
- 52 Week Low
- CMMB $0.87
- DXST $0.85
- 52 Week High
- CMMB $2.55
- DXST $5.74
- Technical
- Relative Strength Index (RSI)
- CMMB 42.55
- DXST N/A
- Support Level
- CMMB $1.17
- DXST N/A
- Resistance Level
- CMMB $1.23
- DXST N/A
- Average True Range (ATR)
- CMMB 0.05
- DXST 0.00
- MACD
- CMMB 0.00
- DXST 0.00
- Stochastic Oscillator
- CMMB 34.11
- DXST 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.